US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
BioSpace1h
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...
Amgen gets expanded FDA label approval for Uplizna
Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...
PMLive2h
Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD
Amgen’s Uplizna (inebilizumab-cdon) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...
Medical Dialogues4h
USFDA grants nod for Amgen Uplizna as first treatment for rare immune disorder
Amgen has announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for UPLIZNA as ...
Amgen announces FDA approval of Uplizna
Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...
Explore more
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4 ...
pharmaphorum4h
Uplizna is first drug FDA-cleared for rare disease IgG4-RD
Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...
Amgen stock rises following FDA approval of UPLIZNA
The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...
Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...